Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 08, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m. ET) in Las Vegas, Nevada.
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
